Abstract Library

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2944 Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer

Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Salvatici M, Zorzino L, Fabiani I, Cardinale D, Fazio N,

Keywords: sST2, Biomarkers, Carcinoid Heart Disease,

#2301 Trends in Management of Gastro-Intestinal Neuroendocrine Tumors in Inflammatory Bowel Diseases: The Contribute of a Case Series.

Introduction: The risk to develop gastro-intestinal malignancies is higher in patients affected by inflammatory bowel diseases (IBD). Apart from colo-rectal cancer, related to a long standing inflammation, there is a growing evidence of neuroendocrine tumors (NETs) in these patients and a correlation between these two diseases has been postulated. We report four cases of NETs in IBD.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rizza S

Authors: Rizza S, Canavese G, Ribaldone D, Cassoni P, Astegiano M,

Keywords: Neuroendocrine tumor, NET, inflammatory bowel disease, Chromogranin, Echo-endoscopy, EUS, IBD,

#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.

Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Brizzi M

Authors: Brizzi M, La Salvia A, Parisi F, Scagliotti G,

Keywords: Carcinoid Hearth Disease, Carcinoid syndrome, Surgery, somatostatin analogues,